Washington, DC 9/2/09; Toronto, Canada 9/2/09; Carlsbad, CA 9/2/09—Danaher has signed a definitive agreement to purchase MDS’s Analytical Technologies division, which includes MDS’s 50% MS joint venture with Life Technologies and its Bioresearch and Drug Discovery product lines. Danaher has also agreed to purchase Life Technologies’ 50% interest in the joint venture. The aggregate purchase price is $1.1 billion in cash, including debt assumed and net of cash acquired, consisting of $650 million for MDS Analytical Technologies and $450 million for Life Technologies’ joint-venture share. “We are excited about the opportunity to acquire two leading brands in the life sciences instrumentation market, which will complement our existing Medical Technologies businesses and present an attractive value creation opportunity,” commented Danaher President and CEO H. Lawrence Culp, Jr. Danaher stated that the acquisition will bring the annual revenues of its life sciences and diagnostics business to more than $2 billion. The transaction is expected to close in the fourth quarter, and is subject to the approval of two-thirds of MDS shareholders, who will cast votes at a special meeting on October 20. MDS plans to use $400–$450 million of the proceeds to buyback stock. MDS also intends to sell its MDS Pharma Services business. (For more, see page 1.)